Neoadjuvant and Adjuvant Pembrolizumab (Pembro) Plus Standard of Care (SOC) in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC): Postoperative Risk Subgroup Analysis of KEYNOTE-689
2025 · International Journal of Radiation Oncology*Biology*Physics · 0 citations
https://doi.org/10.1016/j.ijrobp.2025.08.038